223 related articles for article (PubMed ID: 32442617)
21. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
Vernieri C; Signorelli D; Galli G; Ganzinelli M; Moro M; Fabbri A; Tamborini E; Marabese M; Caiola E; Broggini M; Hollander L; Gallucci R; Vandoni G; Gavazzi C; Triulzi T; Colombo MP; Rizzo AM; Corsetto PA; Pruneri G; de Braud F; Sozzi G; Torri V; Garassino MC
Clin Lung Cancer; 2019 May; 20(3):e413-e417. PubMed ID: 30617039
[TBL] [Abstract][Full Text] [Related]
22. Loss of FGL1 induces epithelial‑mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma.
Bie F; Wang G; Qu X; Wang Y; Huang C; Wang Y; Du J
Int J Oncol; 2019 Sep; 55(3):697-707. PubMed ID: 31322182
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
26. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer.
Trojan J; Brieger A; Raedle J; Esteller M; Zeuzem S
Gut; 2000 Aug; 47(2):272-6. PubMed ID: 10896921
[TBL] [Abstract][Full Text] [Related]
27. Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis.
Ren YH; Zhao FJ; Mo HY; Jia RR; Tang J; Zhao XH; Wei JL; Huo RR; Li QQ; You XM
BMJ Open; 2019 Aug; 9(8):e027185. PubMed ID: 31383697
[TBL] [Abstract][Full Text] [Related]
28. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sanchez-Cespedes M; Parrella P; Esteller M; Nomoto S; Trink B; Engles JM; Westra WH; Herman JG; Sidransky D
Cancer Res; 2002 Jul; 62(13):3659-62. PubMed ID: 12097271
[TBL] [Abstract][Full Text] [Related]
30. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Koyama S; Akbay EA; Li YY; Aref AR; Skoulidis F; Herter-Sprie GS; Buczkowski KA; Liu Y; Awad MM; Denning WL; Diao L; Wang J; Parra-Cuentas ER; Wistuba II; Soucheray M; Thai T; Asahina H; Kitajima S; Altabef A; Cavanaugh JD; Rhee K; Gao P; Zhang H; Fecci PE; Shimamura T; Hellmann MD; Heymach JV; Hodi FS; Freeman GJ; Barbie DA; Dranoff G; Hammerman PS; Wong KK
Cancer Res; 2016 Mar; 76(5):999-1008. PubMed ID: 26833127
[TBL] [Abstract][Full Text] [Related]
31. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
[TBL] [Abstract][Full Text] [Related]
32. Emerging Therapeutic Implications of STK11 Mutation: Case Series.
Laderian B; Mundi P; Fojo T; E Bates S
Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674
[TBL] [Abstract][Full Text] [Related]
33. Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
Lu YF; Chang YH; Chen YJ; Hsieh MS; Lin MW; Hsu HH; Han CL; Chen YJ; Yu SL; Chen JS; Chen HY
Lung Cancer; 2024 May; 191():107791. PubMed ID: 38621342
[TBL] [Abstract][Full Text] [Related]
34. LKB1 gene mutations in Japanese lung cancer patients.
Onozato R; Kosaka T; Achiwa H; Kuwano H; Takahashi T; Yatabe Y; Mitsudomi T
Cancer Sci; 2007 Nov; 98(11):1747-51. PubMed ID: 17711506
[TBL] [Abstract][Full Text] [Related]
35. Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer.
Chen IC; Chang YC; Lu YS; Chung KP; Huang CS; Lu TP; Kuo WH; Wang MY; Kuo KT; Wu PF; Hsueh TH; Shen CY; Lin CH; Cheng AL
Sci Rep; 2016 Feb; 6():21374. PubMed ID: 26877155
[TBL] [Abstract][Full Text] [Related]
36. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
[TBL] [Abstract][Full Text] [Related]
37. Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H; Kluck K; Ball M; Kirchner M; Allgäuer M; Winter H; Herth F; Heußel CP; Pullamsetti SS; Savai R; Yong TTK; Schirmacher P; Peters S; Thomas M; Christopoulos P; Budczies J; Stenzinger A; Kazdal D
Lung Cancer; 2023 Jun; 180():107212. PubMed ID: 37141769
[TBL] [Abstract][Full Text] [Related]
38. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
39. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N; Laurent-Puig P; Mansuet-Lupo A; Legras A; Alifano M; Pallier K; Didelot A; Gibault L; Danel C; Just PA; Riquet M; Le Pimpec-Barthes F; Damotte D; Fabre E; Blons H
Oncotarget; 2017 Apr; 8(14):23831-23840. PubMed ID: 26625312
[TBL] [Abstract][Full Text] [Related]
40. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Qian Y; Galan-Cobo A; Guijarro I; Dang M; Molkentine D; Poteete A; Zhang F; Wang Q; Wang J; Parra E; Panda A; Fang J; Skoulidis F; Wistuba II; Verma S; Merghoub T; Wolchok JD; Wong KK; DeBerardinis RJ; Minna JD; Vokes NI; Meador CB; Gainor JF; Wang L; Reuben A; Heymach JV
Cancer Cell; 2023 Jul; 41(7):1363-1380.e7. PubMed ID: 37327788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
